Stockscreener 앱 받기
3.0371
1.17%
0.0471
전일 마감가:
$2.99
열려 있는:
$3.02
하루 거래량:
291.42K
Relative Volume:
0.18
시가총액:
$165.59M
수익:
$2.81M
순이익/손실:
$-97.34M
주가수익비율:
-1.6873
EPS:
-1.8
순현금흐름:
$-91.47M
1주 성능:
-8.89%
1개월 성능:
-13.82%
6개월 성능:
-60.41%
1년 성능:
-31.09%
1일 변동 폭
$2.955
$3.08
1주일 범위
$2.86
$3.30
52주 변동 폭
$2.86
$13.70
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
명칭
Fulcrum Therapeutics Inc
전화
617-651-8851
주소
26 LANDSDOWNE STREET, CAMBRIDGE, MA
FULC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| FULC | 3.03 | 165.59M | 2.81M | -97.34M | -91.47M | -1.80 |
| VRTX | 449.47 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.65 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.07 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.16 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.06 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-05-04 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-03-10 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-02-28 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-11-15 | 개시 | Goldman | Buy |
| 2022-03-08 | 개시 | Oppenheimer | Outperform |
| 2022-03-03 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-08-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-22 | 개시 | Credit Suisse | Outperform |
| 2021-03-02 | 개시 | Stifel | Buy |
| 2020-10-16 | 개시 | Piper Sandler | Overweight |
| 2020-08-12 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-08-12 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-12 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2019-10-03 | 개시 | H.C. Wainwright | Buy |
| 2019-08-12 | 개시 | BofA/Merrill | Buy |
모두보기
Fulcrum Therapeutics Inc 주식(FULC)의 최신 뉴스
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Facioscapulohumeral Muscular Dystrophy Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Fulcrum Therapeutics, aTyr Pharma, Fulcrum Therapeutics, Hoffmann-La Roche - The Globe and Mail
Fulcrum Therapeutics stock hits 52-week low at $2.87 By Investing.com - Investing.com Canada
Research Analysts Issue Forecasts for FULC FY2024 Earnings - MarketBeat
Simplify Asset Management Inc. Sells 323,518 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2024 Earnings Call Transcript - Insider Monkey
Fulcrum Therapeutics Third Quarter 2024 Earnings: US$0.35 loss per share (vs US$0.39 loss in 3Q 2023) - Yahoo Finance
Fulcrum Therapeutics Inc. (FULC) Tops Q3 EPS by 5c - StreetInsider.com
Fulcrum Therapeutics (NASDAQ:FULC) Receives Neutral Rating from HC Wainwright - MarketBeat
Expert Ratings For Fulcrum Therapeutics - Benzinga
Fulcrum Therapeutics Inc (FULC) Q3 2024 Earnings Call Highlights - GuruFocus.com
Fulcrum Therapeutics Inc (FULC) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst ... - Yahoo Finance
Fulcrum Therapeutics appoints new independent director - Investing.com India
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024 - The Manila Times
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Fulcrum Therapeutics appoints new independent director By Investing.com - Investing.com UK
Fulcrum Therapeutics, Inc. Announces Board Changes - Marketscreener.com
Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference - The Manila Times
Fulcrum Therapeutics (FULC) to Present at Stifel Healthcare Conference | Investor Update | FULC Stock News - StockTitan
Fulcrum Therapeutics (FULC) Scheduled to Post Earnings on Wednesday - MarketBeat
Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET - The Manila Times
Vanguard Group Inc's Strategic Acquisition in Fulcrum Therapeuti - GuruFocus.com
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Short Interest Update - MarketBeat
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Fulcrum Before Q3 Earnings: How Should Investors Play the Stock? - Yahoo Finance
We're Interested To See How Fulcrum Therapeutics (NASDAQ:FULC) Uses Its Cash Hoard To Grow - Yahoo Finance
Ratios in Focus: Analyzing Fulcrum Therapeutics Inc (FULC)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zevra Stock Surges Close to 70% in 3 Months: Here's Why - MSN
The FULC Stock Puzzle: Unraveling Fulcrum Therapeutics Inc’s Fluctuating Performance - The InvestChronicle
Are Smart Investors Making the Right Decision? Fulcrum Therapeutics Inc (FULC) - SETE News
Further weakness as Fulcrum Therapeutics (NASDAQ:FULC) drops 12% this week, taking three-year losses to 88% - Simply Wall St
Fulcrum Therapeutics Inc (FULC) Q2 2024 Earnings Call Highlights: Strong Financial Performance ... - Yahoo Finance
Stock Traders Buy Large Volume of Call Options on Fulcrum Therapeutics (NASDAQ:FULC) - MarketBeat
Fulcrum Stock Tanks 58% in a Month: Buying Opportunity or Risky Bet? - Zacks Investment Research
Dimensional Fund Advisors LP Grows Stock Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat
FMR LLC's Strategic Reduction in Fulcrum Therapeutics Inc Shares - Yahoo Finance
Fulcrum Therapeutics Inc (FULC) stock on the rise: An overview - US Post News
Goldman Sachs Upgrades Fulcrum Therapeutics (FULC) - MSN
Down -57.53% in 4 Weeks, Here's Why Fulcrum Therapeutics (FULC) Looks Ripe for a Turnaround - MSN
An analyst sees good growth prospects for Fulcrum Therapeutics Inc (FULC) - SETE News
Daily Market Movement: Fulcrum Therapeutics Inc (FULC) Sees a 0.84 Increase, Closing at 3.60 - The Dwinnex
Biotech layoff tracker: 13 biotechs cut over 1,400 jobs - The Business Journals
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $9.33 Consensus PT from Analysts - MarketBeat
Fulcrum Therapeutics' SWOT analysis: stock outlook shifts on trial results - Investing.com
Are Fulcrum Therapeutics Inc (FULC) shares a good deal now? - US Post News
FULC Stock on the Rise: A Promising Investment - The InvestChronicle
Fulcrum Therapeutics' SWOT analysis: stock outlook shifts on trial results By Investing.com - Investing.com Australia
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Short Interest Up 41.4% in September - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulcrum Therapeutics, Inc. (FULC) And Encourages Shareholders to Reach Out - AccessWire
Fulcrum Therapeutics Inc (FULC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):